Dyne Therapeutics, Inc. (NASDAQ: DYN) is a Healthcare company (Biotechnology) with a market capitalization of $3.0B. The Maz Rating grades it against the other companies in its sector.
Dyne Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $16.02, Dyne Therapeutics, Inc. trades at 3.2x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -69.7%, return on invested capital of -52.8% and a free cash flow yield of -18.9%. On the balance sheet: a debt-to-equity ratio of 0.26 and a current ratio of 12.99. Over the past 52 weeks the share price ranged from $14.00 to $27.31, with a beta of 1.21.
Dyne Therapeutics, Inc. does not currently pay a dividend.
14 Wall Street analyst ratings cover the stock: 1 Strong Buy, 10 Buy, 2 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.